Abstract:The Keap1 (Kelch-like ECH-associated protein 1)-Nrf2 (nuclear factor erythroid 2-related factor 2)-ARE (antioxidant response element) pathway is the major defending mechanism against oxidative stresses, and directly disrupting the Keap1-Nrf2 protein–protein interaction (PPI) has been an attractive strategy to target oxidative stress-related diseases, including cardiovascular diseases. Here, we describe the design, synthesis, and structure–activity relationships (SARs) of indoline-based compounds as potent Keap1-Nrf2 PPI inhibitors. Comprehensive SAR analysis and thermodynamics-guided optimization identified 19a as the most potent inhibitor in this series, with an IC50 of 22 nM in a competitive fluorescence polarization assay. Further evaluation indicated the proper drug-like properties of 19a. Compound 19a dose-dependently upregulated genes and protein level of Nrf2 as well as its downstream markers and showed protective effects against lipopolysaccharide-induced injury in both H9c2 cardiac cells and mouse models. Collectively, we reported here a novel indoline-based Keap1-Nrf2 PPI inhibitor as a potential cardioprotective agent.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01116?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01116</a>.Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01116/suppl_file/jm0c01116_si_001.csv">CSV</a>)Characterization of the representative intermediates, characterization of the target compounds, Keap1 Kelch domain expression and purification, FP competition assay, binding mode of compound 15 with Keap1, determination of thermodynamic data based on tracer displacement assay, ITC assay, BLI assay, ARE-luciferase activity assay, cell viability assay, RNA extraction and qRT-PCR analysis, Western blot analysis, IL-1β, IL-6, and TNF-α production, evaluation of GSH/GSSG ratio, detection of ROS level, animal experiments, statistical analysis and 1H NMR, 13C NMR, HRMS and HPLC spectra for representative target compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01116/suppl_file/jm0c01116_si_002.pdf">PDF</a>)This article has not yet been cited by other publications.

Research progress on the role and inhibitors of Keap1 signaling pathway in inflammation

Nrf2 Signaling Pathway: Pivotal Roles in Inflammation.

The Keap1–Nrf2–ARE Pathway As a Potential Preventive and Therapeutic Target: an Update

Updated Research and Applications of Small Molecule Inhibitors of Keap1-Nrf2 Protein-Protein Interaction: a Review.

Recent progress and applications of small molecule inhibitors of Keap1–Nrf2 axis for neurodegenerative diseases

The role of Keap1-Nrf2 signaling pathway in the treatment of respiratory diseases and the research progress on targeted drugs

Medicinal Chemistry Insights into the Development of Small-Molecule Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors.

The research progression of direct NLRP3 inhibitors to treat inflammatory disorders

Small Molecules Inhibiting Keap1-Nrf2 Protein-Protein Interactions: A Novel Approach to Activate Nrf2 Function

Regulation of Keap1-Nrf2 signaling in health and diseases

KEAP1-NRF2 protein-protein interaction inhibitors: Design, pharmacological properties and therapeutic potential

Recent Advances of Natural Polyphenols Activators for Keap1‐Nrf2 Signaling Pathway

Discovery and Development of Kelch-Like Ech-Associated Protein 1. Nuclear Factor Erythroid 2-Related Factor 2 (keap1:Nrf2) Protein-Protein Interaction Inhibitors: Achievements, Challenges, and Future Directions

Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (Review)

An Overview of Nrf2 Signaling Pathway and Its Role in Inflammation

Function and inhibition of P38 MAP kinase signaling: Targeting multiple inflammation diseases

KEAP1, a cysteine-based sensor and a drug target for the prevention and treatment of chronic disease

Recent Progress in the Development of Small Molecule Nrf2 Activators: a Patent Review (2017-Present)

CPUY192018, a Potent Inhibitor of the Keap1-Nrf2 Protein-Protein Interaction, Alleviates Renal Inflammation in Mice by Restricting Oxidative Stress and NF-κB Activation.

Design, Synthesis, and Structure–Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Protein–Protein Interaction Inhibitors

Recent Progress on the Discovery of NLRP3 Inhibitors and their Therapeutic Potential